PharmExec Blog

Pharma Showing Signs of Stability Despite Patent Cliffs

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData. Read More »

Posted in Deals, Strategy | Tagged , , , , , , | Leave a comment

Tufts Pegs Drug Development Cost at $2.6 billion – MSF Cries Foul

A cool $2.6 billion is the going rate to develop and gain market approval for a drug, according to the recent study by the Tufts Center for the Study of Drug Development (CSDD). Read More »

Posted in R&D | Tagged , , | Leave a comment

Actavis Marches Ahead with Acquisition Spree

Actavis’s agreed purchase of Allergan for around $66 billion will help grow the Dublin-based specialty pharma firm to a $22 billion healthcare company in 2015 — a “dramatic elevation”, given the $8.7 billion revenues it recorded in 2013, reports research and consulting firm GlobalData. Read More »

Posted in Deals | Tagged , , , | Leave a comment

CMS Struggles to Fix Sunshine System

The feds have “a long way to go” to get the Open Payments system operating effectively and user friendly, according to officials in charge of the financial disclosure program. “Sunshine” went live September 30, 2014, as scheduled, but incomplete and contradictory data listings made it necessary to withhold nearly one-third of financial transaction reports from pharma and medical device companies.

“This was our first shot at getting the data out there,” acknowledged Doug Brown, acting director of the Data Sharing & Partnership Group at the Center for Program Integrity, which runs the Open Payments program for the HHS Centers for Medicare and Medicaid Services (CMS). Read More »

Posted in FDA, Op-Ed, Regulatory | Tagged , , , , , | Leave a comment

No-One's in Charge of Pharmaceuticals in Europe!

Peter O’Donnell’s recent Applied Clinical Trials blog, ‘Who’s in charge of Medicines in Brussels?‘, has been overtaken by history, with the departure of Guido Rasi from his post of Executive Director of the European Medicines Agency.

At a time of flux in the European context for pharmaceuticals, Rasi’s moderate manner and capacity for strategic thinking were one reassurance amid so much uncertainty, writes Peter, and his removal is to be lamented.

Click here for more.

Posted in Europe, Regulatory | Tagged , , | Leave a comment
  • Categories

  • Meta